Histogenics (HSGX) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts HSGX Hot Sheet
Join SI Premium – FREE
Histogenics (NASDAQ: HSGX) reported Q2 EPS of ($0.25), $0.05 better than the analyst estimate of ($0.30).
For earnings history and earnings-related data on Histogenics (HSGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) Tops Q3 EPS by 60c, Beats on Revenue; Offers FY26 EPS Guidance
- V.F. Corp. (VFC) Tops Q2 EPS by 17c, Beats on Revenue
- Group 1 Automotive (GPI) Misses Q3 EPS by 44c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
